Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Clinician and Patient Factors Associated With Long-Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies.
Journal: Arthritis care & research
Published: December 10, 2025
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients.
Journal: Arthritis care & research
Published: May 14, 2025
Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins.
Journal: RMD open
Published: August 02, 2024
TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapy.
Journal: Cellular & molecular immunology
Published: July 10, 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: June 27, 2024
New onset work disability in rheumatoid arthritis is an underrecognized cardiovascular risk factor: A retrospective cohort study using the CorEvitas registry.
Journal: Seminars in arthritis and rheumatism
Published: January 11, 2024
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry.
Journal: The Journal of rheumatology
Published: December 20, 2023
Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients.
Journal: Seminars in arthritis and rheumatism
Published: November 10, 2023
Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry.
Journal: Arthritis care & research
Published: October 11, 2023
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study.
Journal: Rheumatology and therapy
Published: August 18, 2023
A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis.
Journal: Rheumatology and therapy
Published: August 03, 2023
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: March 31, 2023
Last Updated: 09/26/2026